USA - NASDAQ:ARNA - Common Stock
ARNA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. Both the profitability and financial health of ARNA have multiple concerns. ARNA has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -78.55% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | -1141511.11% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Altman-Z | 27.53 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.59 | ||
Quick Ratio | 8.59 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | -10.44 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
99.99
+0.06 (+0.06%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 114173.77 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 9.16 | ||
P/tB | N/A | ||
EV/EBITDA | -10.44 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -78.55% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | -1141511.11% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8.59 | ||
Quick Ratio | 8.59 | ||
Altman-Z | 27.53 |